ReviewThe Lancet. Infectious diseases2022
Definition, diagnosis, and management of COVID-19-associated pulmonary mucormycosis: Delphi consensus statement from the Fungal Infection Study Forum and Academy of Pulmonary Sciences, India.
Review in The Lancet. Infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 45 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 2 syntheses or guidelines pooled it, 83 citations in OpenAlex.
- Sensitivity and Specificity of Polymerase Chain Reaction in Blood and Bronchoalveolar Lavage Samples for Mucormycosis: A Bayesian Diagnostic Test Accuracy Meta-Analysis.Mycopathologia · 2025Pooled it
- Mucormycosis in Human Immunodeficiency Virus-Infected Individuals: A Systematic Review of Case Reports.Mycopathologia · 2023Pooled it
- Pulmonary mucormycosis: Imaging findings and implications.Lung India : official organ of Indian Chest Society · 2026Article
- CT manifestations of pulmonary mucormycosis: Influence of risk factor, symptom duration, and glycemic control.Lung India : official organ of Indian Chest Society · 2026Article
- Clinical characteristics and risk factors for mortality in pulmonary mucormycosis among patients with non-hematologic malignancies.BMC pulmonary medicine · 2026Article
- [Chinese expert consensus on infection management in multiple myeloma patients treated with bispecific antibody (2026)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026Article
- Post-COVID-19 Jaw Osteonecrosis: A Narrative Review.Medicina (Kaunas, Lithuania) · 2026Review
- Amphotericin B promotes respiratory viral entry by enhancing late endosomal maturation and fusion via glucocerebrosidase-mediated ceramide remodeling.Nature communications · 2026Article
- Efficacy and safety of amphotericin B colloidal dispersion in the treatment of mucormycosis: a real-world observation.BMC infectious diseases · 2026Observational
- Epidemiological profile and clinical outcomes of patients with mucormycosis: the multicenter retromucor study from Türkiye (2004-2024).European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Fatal Pharyngeal Cellulitis Caused byInfection and drug resistance · 2026Article
- Lineage-specific endosymbiosis in Mucorales: restriction ofCurrent research in microbial sciences · 2026Article
- Bronchoscopic local instillation of amphotericin B deoxycholate as adjunctive therapy for pulmonary mucormycosis with inadequate response to posaconazole: a retrospective case series.Frontiers in medicine · 2026Article
- Antifungal Susceptibility Testing Experience in the Management of Culture-Positive Mucormycosis: Observation from a Large Healthcare System.Journal of fungi (Basel, Switzerland) · 2026Article
- Clinical characteristics of tracheobronchial mucormycosis: a retrospective analysis of twenty cases.Annals of medicine · 2025Article
- Can We Have Guidelines or Just Guidance for Rare Fungal Infections?Journal of fungi (Basel, Switzerland) · 2025Article
- Article
- Recent Trend of Surge in Pulmonary involvement in Sinonasal Mucormycosis: A Case Series: Pulmonary involvement in Sinonasal Mucormycosis.Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India · 2025Article
- Appendiceal Perforation and Abdominal Wall Infection Caused by Invasive Mucormycosis in a Child with Acute Leukemia.Infection and drug resistance · 2025Article
- Viral reactivations and fungal infections in nonresolving acute respiratory distress syndrome.European respiratory review : an official journal of the European Respiratory Society · 2025Review
Corrections and comments
- Erratum issued
Authors and funding
27 authors at 13 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
COVID-19-associated pulmonary mucormycosis (CAPM) remains an underdiagnosed entity. Using a modified Delphi method, we have formulated a consensus statement for the diagnosis and management of CAPM. We selected 26 experts from various disciplines who are involved in managing CAPM. Three rounds of the Delphi process were held to reach consensus (≥70% agreement or disagreement) or dissensus. A consensus was achieved for 84 of the 89 statements. Pulmonary mucormycosis occurring within 3 months of COVID-19 diagnosis was labelled CAPM and classified further as proven, probable, and possible. We recommend flexible bronchoscopy to enable early diagnosis. The experts proposed definitions to categorise dual infections with aspergillosis and mucormycosis in patients with COVID-19. We recommend liposomal amphotericin B (5 mg/kg per day) and early surgery as central to the management of mucormycosis in patients with COVID-19. We recommend response assessment at 4-6 weeks using clinical and imaging parameters. Posaconazole or isavuconazole was recommended as maintenance therapy following initial response, but no consensus was reached for the duration of treatment. In patients with stable or progressive disease, the experts recommended salvage therapy with posaconazole or isavuconazole. CAPM is a rare but under-reported complication of COVID-19. Although we have proposed recommendations for defining, diagnosing, and managing CAPM, more extensive research is required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.